Roth Capital Previews bluebird bio (BLUE) Ahead of EHA Abstract
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
bluebird bio (BLUE) PT Raised to $200 at BMO Capital Ahead of SCD Data for LentiGlobin at EHA
May 20, 2015 7:43 AM EDTBMO Capital analyst Jim Birchenough reiterated an Outperform rating and boosted his price target on bluebird bio (NASDAQ: BLUE) to $200.00 (from $170.00) as the company expected to release initial data for its LentiGlobin gene therapy in Sickle Cell Disease (SCD) on Thursday in an abstract release for the European Hematology Association (EHA) annual... More
bluebird bio (BLUE) PT Raised to $192 at Roth Capital
May 19, 2015 1:29 PM EDTRoth Capital analyst Debjit Chattopadhyay reiterated a Buy rating and boosted his price target on bluebird bio (NASDAQ: BLUE) to $192.00 (from $145.00) after EU and US regulators agreed to an accelerated development path for LentiGlobin in beta-thal.
Chattopadhyay commented, "Assuming no material changes to... More
bluebird bio (BLUE) PT Raised to $222 at Wedbush
May 19, 2015 12:46 PM EDTWedbush analyst David Nierengarten reiterated an Outperform rating and boosted his price target on bluebird bio (NASDAQ: BLUE) to $222.00 (from $146.00) on the earlier launch timing on regulatory update.
Nierengarten commented, "BLUE announced this morning that following discussions with EU and US regulators, both agencies have agreed to an accelerated development path for LentiGlobin in beta-thal.... More
bluebird bio (BLUE) Updates on Potential Approval Pathways for LentiGlobin BB305
May 19, 2015 6:18 AM EDTbluebird bio (NASDAQ: BLUE) announced that it has met with regulatory authorities in Europe and the United States to discuss potential approval pathways for its LentiGlobin BB305 product candidate for the treatment of beta-thalassemia major. These discussions have resulted in general agreement from both agencies regarding bluebird bios development plans, which could potentially result in accelerated approvals.
We are very pleased with the outcome of these recent regulatory interactions, commented David Davidson, M.D., chief medical officer. We look forward to advancing our beta-thalassemia major program based on data both from our... More
